Skip to main content

Table 3 Comparison of flare and non-flare group in SACQ and SQCQ

From: Treatments and outcomes in Chinese patients with serologically active clinically quiescent systemic lupus erythematosus: a retrospective observational study

  SACQ (170) SQCQ (187)
Flare (56) Non-flare (114) p Flare (29) Non-flare (158) p
Age at diagnosis (years) 30.95 ± 13.88 32.65 ± 14.61 0.469 34.19 ± 14.14 39.42 ± 15.15 0.086
Gender (male to female) 8:48 13:101 0.624 2:27 17:141 0.765
Recurrence time or follow-up timea (months) 21.82 (13.39, 31.59) 19.23 (10.02, 34.32) 0.440 26.43 (16.72, 41.97) 22.92 (11.63, 43.65) 0.361
Duration of serological activity/inactivity before SACQ/SQCQ (months) 13.58 (6.94, 25.19) 15.49 (7.31, 25.87) 0.771 11.10 (5.77, 21.72) 8.88 (3.01, 15.99) 0.115
Time to SACQ/SQCQb (months) 23.88 (13.03, 50.68) 22.07 (12.16, 50.62) 0.562 21.0 (11.85, 58.65) 17.28 (9.84, 36.53) 0.241
Dose of corticosteroids at the start of SACQ/SQCQ 7.5 (5.0, 7.5) 7.5 (6.25, 7.5) 0.096 7.5 (5.0, 7.5) 7.5 (5.0, 7.5) 0.608
Taking antimalarials at the start of SACQ/SQCQ 40/56 (71.4%) 90/114 (78.9%) 0.277 22/29 132/158 0.319
Taking immunosuppressants at the start of SACQ/SQCQ 29/56 (51.8%) 67/114 (58.8%) 0.414 15/29 84/158 0.886
Dose of corticosteroidsc (mg) when relapsed or at the end of follow-up 5.0 (2.81,7.5) 3.75 (1.25, 5.0) 0.011 5.0 (0, 5.0) 3.75 (1.25, 5.0) 0.489
Taking antimalarials when relapsed or at the end of follow-up 36/56 (64.3%) 97/114 (85.1%) 0.002 17/29 (58.6%) 135/158 (85.4%) 0.001
Taking immunosuppressants when relapsed or at the end of follow-up 23/56 (41.1%) 69/114 (60.5%) 0.017 10/29 (34.5%) 87/158 (55.1%) 0.041
Anti-dsDNA (+) 41/56 (73.2%) 96/114 (84.2%) 0.101
Hypocomplementemia 26/56 (46.4%) 36/114 (31.6%) 0.064
Symptoms at initial diagnosis.
 LN 16/56 (28.6%) 46/114 (40.4%) 0.175 10/29 (34.5%) 58/158 (36.7%) 0.819
 NPSLE 2/56 (3.6%) 6/114 (5.3%) 1.000 1/29 (3.4%) 10/158 (6.3%) 0.860
 Thrombocytopenia 9/56 (16.1%) 14/114 (12.3%) 0.485 6/29 (20.7%) 30/158 (19.0%) 0.831
 Hemolytic anemia 5/56 (8.9%) 9/114 (7.9%) 0.776 1/29 (3.4%) 13/158 (8.2%) 0.606
 Pulmonary hypertension 3/56 (5.4%) 1/114 (0.9%) 0.105 1/29 (3.4%) 4/158 (2.5%) 1.000
 Myocardial involvement 0/56 (0) 0/114 (0) NA 0/29 (0) 3/158 (1.9%) 1.000
 ILD 2/56 (3.6%) 1/114 (0.9%) 0.253 0/29 (0) 6/158 (3.8%) 0.622
 Alveolar hemorrhage 0/56 (0) 0/114 (0) NA 0/29 (0) 0/29 (0) NA
 Smooth muscle involvement 0/56 (0) 6/114 (5.3%) 0.179 0/29 (0) 5/158 (3.2%) 0.730
 Polyserositis 2/56 (3.6%) 6/114 (5.3%) 1.000 1/29 (3.4%) 7/158 (4.4%) 1.000
 APS 2/56 (3.6%) 5/114 (4.4%) 1.000 1/29 (3.4%) 4/158 (2.5%) 1.000
 TTP or TMA 0/56 (0) 0/114 (0) NA 0/29 (0) 0/29 (0) NA
 Secondary SS 5/56 (8.9%) 14/114 (12.3%) 0.611 3/29 (10.3%) 22/158 (13.9%) 0.823
  1. aThe period from the time they reached the SACQ/SQCQ to the time of recurrence (flare group) or at the end of follow-up (non-flare group)
  2. bThe period from the onset of SLE to the time they reached SACQ
  3. cCorticosteroid doses were converted to milligrams (mg) of prednisone equivalent